Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in
intravascular robotics, today announced that Marjorie L. Bowen has
been appointed as a Director, effective as of July 16, 2013. The
appointment increases the Company's board membership to nine, eight
of whom are independent. Ms. Bowen brings to the board nearly 25
years of experience in advising both public and private companies
as an investment banker and corporate director.
"Marjorie brings to Hansen Medical significant financial
expertise gained as a trusted advisor to companies both as an
investment banker, as well as an experienced corporate director,"
said Mike Eagle, Chairman of the Board for Hansen Medical. "We look
forward to working with her and leveraging her extensive Wall
Street experience."
Currently, Ms. Bowen serves on the boards of Dune Energy, Inc.
(OTCBB: DUNR), an oil and gas exploration and development company,
where she is the Chair of the Nominating and Corporate Governance
Committee, and Global Aviation Holdings, Inc., a privately-held
transportation services company, where she is the Chair of the
Audit Committee and also a member of the Finance Committee. Ms.
Bowen joined the Board of Global Aviation Holdings after advising
its predecessor on its acquisition of World Airways in late 2007;
she was the only independent director for two years following the
acquisition, and was also the only director to continue to serve
following a restructuring in 2012. In addition to her current
director roles, Ms. Bowen's previous board affiliations include The
Talbots, Inc. (which was listed on the NYSE during her tenure),
Euramax International, Texas Industries, Inc. (traded on the NYSE
under the symbol TXI), Vertis, Inc., and Vertis Holdings, Inc.
Prior to Ms. Bowen's corporate director roles, she spent nearly
20 years in increasingly senior investment banking-related
positions at Houlihan Lokey Howard & Zukin, Inc., an
independent, advisory-focused global investment bank, where she
advised the boards and management teams of public companies on
transactional, strategic and other shareholder matters, served as a
product and practice leader, and headed the firm's industry leading
fairness opinion practice. During her nearly two decades at
Houlihan Lokey, Ms. Bowen led transaction teams that provided
financial advice on corporate strategic alternatives, shareholder
value maximization strategies, sales, mergers and acquisitions,
takeover defense, as well as other capital transactions, such as
equity reorganizations and exchanges, asset sales and financings.
She also served on the management committee of Houlihan Lokey's
financial advisory practice, where she played an active role in
managing the numerous products and services executed across the
firm, and was also responsible for all regulatory compliance, risk
management, planning and forecasting, competitive assessments,
marketing, and advertising programs, and staff development relating
to Houlihan Lokey's top-ranked fairness opinion practice. Ms. Bowen
was the most senior female executive at the Houlihan Lokey from
1991 until her retirement in December 2007. She has been frequently
quoted in the press and delivered numerous speeches on corporate
governance trends, shareholder matters and transactional
issues.
"Hansen Medical's EP and vascular robotics business are
experiencing significant momentum, and I am pleased to be joining
the Board at such a critical juncture in the Company's history,"
said Ms. Bowen. "I look forward to lending my financial expertise
as the Company continues to pave its path to profitability."
About Hansen Medical, Inc. Hansen Medical,
Inc., based in Mountain View, California, is a global leader in
intravascular robotics, developing products and technology designed
to enable the accurate positioning, manipulation and control of
catheters and catheter-based technologies. The Company's Magellan™
Robotic System, Magellan Robotic Catheter and related accessories,
which are intended to facilitate navigation to anatomical targets
in the peripheral vasculature and subsequently provide a conduit
for manual placement of therapeutic devices, have undergone both CE
marking and 510(k) clearance and are commercially available in the
European Union and the U.S. In the European Union, the Company's
Sensei® X Robotic Catheter System, Artisan Control Catheter and
Artisan Extend® Control Catheter are cleared for use during
electrophysiology (EP) procedures, such as guiding catheters in the
treatment of atrial fibrillation (AF), and the Lynx® Robotic
Ablation Catheter is cleared for the treatment of AF. This robotic
catheter system is compatible with fluoroscopy, ultrasound, 3D
surface map and patient electrocardiogram data. In the U.S. the
Company's Sensei X Robotic Catheter System and Artisan Control
Catheter are cleared by the U.S. Food and Drug Administration for
manipulation and control of certain mapping catheters in EP
procedures. In the United States, the Sensei System is not approved
for use in guiding ablation procedures; this use remains
experimental. The U.S. product labeling therefore provides that the
safety and effectiveness of the Sensei X System and Artisan Control
Catheter for use with cardiac ablation catheters in the treatment
of cardiac arrhythmias, including AF, have not been established.
Additional information can be found at www.hansenmedical.com.
Forward-Looking Statements
This press release contains forward-looking statements
regarding, among other things, statements relating to goals, plans,
objectives, milestones and future events. All statements, other
than statements of historical fact, are statements that could be
deemed forward-looking statements, including statements containing
the words "plan," "expects," "potential," "believes," "goal,"
"estimate," "anticipates," and similar words. These statements are
based on the current estimates and assumptions of our management as
of the date of this press release and are subject to risks,
uncertainties, changes in circumstances and other factors that may
cause actual results to differ materially from the information
expressed or implied by forward-looking statements made in this
press release. Examples of such statements include statements about
the anticipated growth in Hansen Medical intravascular robotics
technology for EP and vascular applications. Important factors that
could cause actual results to differ materially from those
indicated by such forward-looking statements include, among others:
engineering, regulatory, manufacturing, sales and customer service
challenges in developing new products and entering new markets; the
commercial viability of our products in the electrophysiology and
vascular markets; potential safety and regulatory issues that could
slow or suspend our sales; the effect of economic conditions on
capital spending by our potential customers; the uncertain
timelines for the sales cycle for newly introduced products; the
rate of adoption of our systems and the rate of use of our
catheters; the scope and validity of intellectual property rights
applicable to our products; competition from other companies; our
ability to recruit and retain key personnel; our ability to
maintain our remedial actions over previously reported material
weaknesses in internal controls over financial reporting; our
ability to manage expenses and cash flow, and obtain additional
financing; and other risks more fully described in the "Risk
Factors" section of our Quarterly Report on Form 10-Q for the
quarter ended March 31, 2013 filed with the SEC on May 10, 2013 and
the risks discussed in our other reports filed with the SEC. Given
these uncertainties, you should not place undue reliance on the
forward-looking statements in this press release. We undertake no
obligation to revise or update information herein to reflect events
or circumstances in the future, even if new information becomes
available.
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei, Artisan, Artisan Extend and Lynx are registered
trademarks, and Magellan is a trademark of Hansen Medical, Inc. in
the United States and other countries.
Investor Contacts: Peter J. Mariani Chief Financial
Officer Hansen Medical, Inc. 650.404.5800 FTI Consulting,
Inc. Brian Ritchie 212.850.5683 Email Contact John Capodanno
212.850.5705 Email Contact
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024